The authors sincerely apologize for the inaccuracies made during the revision that a product line has been associated with the wrong company. They wish to make the following corrections to the previous paper \[[@B1-jcm-09-02630]\].

On page 2 of the published paper (Section 2.1. *MRD in the Bone Marrow*), the authors would like to replace the inaccurate sentence:

Other non-commercial NGS technologies are under investigation: the LymphoTrack^®^ assay (Invitrogen, US-MA) has been recently validated in a phase II study \[[@B2-jcm-09-02630]\], and the EuroClonality-NGS Consortium (an international group of 21 academic laboratories experienced in NGS) has recently validated IG/TR NGS assays and a bioinformatic tool for an academic study on MRD \[[@B3-jcm-09-02630]\].

With the following sentence:

Other non-commercial NGS technologies are under investigation: the LymphoTrack^®^ assay (Invivoscribe, Inc., US-CA) has been recently used to establish IGH chain clonality for NGS characterization of B-Cell and plasma cell neoplasms \[[@B4-jcm-09-02630]\]. Martinez-Lopez et al. validated an "in-house deep-sequencing" method in a phase II study by using standardized primers developed by the Biomed-2 Concerted Action, in order to amplify all IGH or IGK sequences \[[@B2-jcm-09-02630]\]. Furthermore, the EuroClonality-NGS Consortium (an international group of 21 academic laboratories experienced in NGS) has recently validated IG/TR NGS assays and a bioinformatic tool for an academic study on MRD \[[@B3-jcm-09-02630]\].

The published version will be updated online on the article webpage, with a reference to this Erratum.
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